TELA Bio Reports Second Quarter 2025 Financial Results

Core Insights - TELA Bio, Inc. reported a significant revenue growth of 26% year-over-year for Q2 2025, reaching $20.2 million, driven by increased unit sales and new customer acquisitions [4][9] - The company is at a pivotal point with a strong product portfolio and leadership changes aimed at optimizing sales and market access [3][9] - TELA Bio reiterated its full-year revenue guidance of $85.0 million to $88.0 million, indicating a projected growth of 23% to 27% compared to 2024 [10][9] Financial Performance - Revenue for Q2 2025 was $20.2 million, a 26% increase from $16.1 million in Q2 2024, with a sequential growth of 9% from Q1 2025 [4][9] - Gross profit was $14.1 million, representing a gross margin of 69.8%, up from 68.8% in the same quarter of the previous year [5] - Operating expenses increased to $23.2 million in Q2 2025 from $22.6 million in Q2 2024, primarily due to higher commission costs and professional fees [6] Loss and Cash Position - Loss from operations decreased to $9.1 million in Q2 2025 from $11.6 million in Q2 2024, while net loss improved to $9.9 million from $12.6 million [7] - As of June 30, 2025, cash and cash equivalents totaled $35.0 million, down from $52.7 million at the end of 2024 [7][15] Product and Market Developments - The company experienced increased demand for its OviTex® and OviTex PRS products, with year-over-year revenue growth of approximately 12% and 53%, respectively [9] - TELA Bio announced the European commercial launch of OviTex Inguinal for robotic and laparoscopic hernia repair, expanding its market presence [9]